HLA-B27
Human leukocyte antigens (HLA) are cell surface proteins that play a fundamental role in distinguishing between endogenous and foreign structures in the body. One of these cell surface antigens is HLA-B27, which can be found on virtually all body cells. The association between HLA-B27 and ankylosing spondylitis has been known for over 30 years. Over 90% of all patients with ankylosing spondylitis carry the HLA-B27 gene which however is only present in 8% of the “healthy” population. Thus the molecular genetic detection of HLA-B27 has a very high diagnostic significance for the probability of developing this disease.
Ankylosing spondylitis is a chronic rheumatic disease which mainly affects the spine. The early symptomatology of the disease leads to movement limitations of the lumbar spine. Further on in the course of the disease, the symptoms may worsen to the point of hardening of the bones of the spine.
The first signs of the disease are frequently unspecific and are generally not associated with the disease. There is generally a time period of 5-10 years between the initial symptoms and a definite diagnosis. However, an early diagnosis is of crucial importance, since the course of the disease can positively be influenced when the disease is diagnosed early on.
Based on the high diagnostic significance, it is recommended that all patients with inflammatory back pain undergo an HLA-B27 determination. Along with the clarification of additional parameters, for example, the presence of a positive family history, the test result makes a definite diagnosis possible.
The choice is yours: Two technologies and test systems for your individual result
Product range
Your fluorescence-based test system for the definite detection of the HLA-B27 gene.
Your benefits with FluoroType® HLA-B27 VER 1.0
- Definite Results: All relevant subtypes of HLA-B27 are detected.
- Early diagnosis: The high diagnostic value obtained through genotyping provides an important therapeutic head start. This allows treatment measures to be taken early and helps to control the course of the disease.
- Innovative technology: FluoroType® HLA-B27 VER 1.0 is based on an innovative fluorescence-based technology enabling fast and reliable results for efficient laboratory diagnostics.
- User-friendly: Limited use of pipettes saves time and guarantees efficient routine diagnostic procedures.
At a glance
Molecular genetic fluorescence-based test system for the definite detection of the HLA-B27 gene
Starting material:
Whole blood
DNA Isolation:
GXT Blood Extraction Kit VER 2.0 (with GenoXtract®)
Instrument for Amplification and Detection:
FluoroCycler® 12
FluoroCycler® XT
Technology:
FluoroType® technology
Your test system for the definite detection of the HLA-B27 gene.
Our GenoQuick® HLA-B27 VER 2.0 test system offers you definitive and easy determination of the HLA-B27 gene and saves crucial time through early diagnosis of the patient.
Your benefits with GenoQuick® HLA-B27 VER 2.0
- Definite result: all relevant subtypes of HLA-B27 are detected. This allows for a definite diagnosis.
- No living cells are needed for detection: in contrast to flow cytometry, molecular genetic detection allows for samples to also be stored over a longer period of time. In this way, smaller production runs can also be efficiently processed.
- Simple evaluation: the presence of the HLA-B27 gene is shown by a single band on the test strip and can thus be seen at a glance.
At a glance
Rapid molecular genetic assay for detection of the HLA-B27 gene
Starting material:
EDTA/Citrate blood
DNA Isolation:
GENO•CARD VER 1.0
Technology:
GenoQuick® technology
Downloads:
Please contact your local representative for availability in your country.
Not for sale in the USA.
Legal Manufacturer is Hain Lifescience GmbH – A Bruker Company
